Last reviewed · How we verify

Durata Therapeutics Inc., an affiliate of Allergan plc — Portfolio Competitive Intelligence Brief

Durata Therapeutics Inc., an affiliate of Allergan plc pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Vancomycin / Linezolid Vancomycin / Linezolid phase 3 glycopeptide antibiotic / oxazolidinone D-alanyl-D-alanine terminus of cell wall precursors / 50S ribosomal subunit Infectious Disease
IV Dalbavancin IV Dalbavancin phase 3 Lipoglycopeptide antibiotic D-Ala-D-Ala peptidoglycan precursors Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. Melinta Therapeutics, Inc. · 1 shared drug class
  3. University of Colorado, Denver · 1 shared drug class
  4. University of Pennsylvania · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Durata Therapeutics Inc., an affiliate of Allergan plc:

Cite this brief

Drug Landscape (2026). Durata Therapeutics Inc., an affiliate of Allergan plc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/durata-therapeutics-inc-an-affiliate-of-allergan-plc. Accessed 2026-05-18.

Related